专利检索 ap:("Jiangnan University") AND inv:"Caixin NI" 第 1 页

1.

发明公开
Lactobacillus gasseri capable of alleviating and treating hyperuricemia 审中-公开

公开(公告)号：US20240000871A1

公开(公告)日：2024-01-04

申请号：US18335275

申请日：2023-06-15

申请人： Jiangnan University

发明人： Gang WANG , Caixin NI , Linlin WANG , Jianxin ZHAO , Hao ZHANG , Wei CHEN

IPC分类号： A61K35/747 , C12N1/20 , A61P19/06

CPC分类号： A61K35/747 , C12N1/205 , A61P19/06 , C12R2001/225

摘要： The present disclosure discloses Lactobacillus gasseri capable of alleviating and treating hyperuricemia, which belongs to the technical field of microorganisms. The L. gasseri CCFM1133 of the present disclosure can reduce serum uric acid levels and the activity of serum and liver xanthine oxidase (XOD) of mice with hyperuricemia, and reduce the occurrence of hyperuricemia and gout; regulate glucose and serum triglyceride (TG) levels of patients with hyperuricemia, increase the activity of liver catalase (CAT) and glutathione peroxidase (GSH-Px); increase the expression of ileum ABCG2, promote the excretion of intestinal uric acid; and increase intestinal short-chain fatty acid levels to promote health. The L. gasseri CCFM1133 of the present disclosure can be used for preparing food, functional food or medicines, and has a wide application prospect.

2.

发明公开
Lactobacillus reuteri CCFM1132 capable of relieving hyperuricemia and application thereof 审中-公开

公开(公告)号：US20230381254A1

公开(公告)日：2023-11-30

申请号：US18335248

申请日：2023-06-15

申请人： Jiangnan University

发明人： Gang WANG , Caixin NI , Yuxing ZHENG , Linlin WANG , Jianxin ZHAO , Hao ZHANG , Wei CHEN

IPC分类号： A61K35/747 , C12N1/20 , A61P19/06

CPC分类号： A61K35/747 , C12N1/205 , A61P19/06

摘要： The present disclosure discloses Lactobacillus reuteri CCFM1132 capable of relieving hyperuricemia and application thereof, which belongs to the technical field of microorganisms. The L. reuteri CCFM1132 can reduce serum uric acid levels of mice with hyperuricemia, inhibit the activity of serum and liver xanthine oxidase (XOD), and reduce the occurrence of hyperuricemia and gout; reduce serum creatinine levels, reduce serum total triglyceride (TG) levels, and inhibit the activity of serum alkaline phosphatase (ALP); and promote the expression of ileum uric acid transporter ABCG2. The L. reuteri CCFM1132 of the present disclosure can be used for preparing functional bacterial agents, food and medicines for relieving hyperuricemia and gout, and has a wide application prospect.